Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of spartalizumab plus dabrafenib and trametinib versus placebo plus dabrafenib and trametinib in previously untreated BRAF V600-mutant unresectable or metastatic melanoma
MOH_2017-05-25_000434Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Spartalizumab + dabrafenib + trametinib with Placebo + dabrafenib + trametinib (2 arms). Primary endpoint: Progression-free survival. Started Apr 2017; status: completed.
02
Drugs
spartalizumabdabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2017-05-25_000434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-25_000434.